Advances of pathological diagnosis of lung cancer based on clinical needs.
10.3760/cma.j.cn112151-20221112-00949
- Author:
Yang QU
1
;
Jian Ming YING
1
Author Information
1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Lung Neoplasms/drug therapy*;
Prognosis;
Immunotherapy
- From:
Chinese Journal of Pathology
2023;52(2):103-106
- CountryChina
- Language:Chinese
-
Abstract:
Pathological diagnosis of lung cancer keep updating and developing, in order to meet the clinical needs in the era of precision medicine. It mainly involves the advances of histological subtype classification, molecular testing for targeted therapy, biomarkers detection for immunotherapy and the pathological evaluation for neoadjuvant therapy. Nowadays, pathological diagnosis of lung cancer present a multidisciplinary model including clinical medicine, radiology and pathology. It is gradually moving towards standardization with expection to provide better guidance for clinical treatment and prognosis.
